WO 2005/007699

PCT/GB2004/003059


13/24

Figure 19

10 Human IL-13 MALLLTTVIALTCLGGFASP PVPPSTAL ELIBELVNIT Cynomolgus IL-13 MALLLTTVIALTCLGGFASP PVPPSTAL ELIBELVNIT MALLLTTVIALTCLGGFASP PVPPSTAL ELIEELVNTT 50 60 80 Human IL-13 QNQKAPLCNGSMVWSINLTAG YCAALESLINVSGCSAIE QNQKAPLCNGSMVWSINLTAG YCAALESLINVSGCSAIE Cynomolgus IL-13 QNQKAPLCNGSMVWSINLTAG YCAALESLINVSGCSAIE 90 100 Human II-13 KTQRML GPCPHKVSAGQFSSL VRDTKI EVAQFVKDLL Cynomolgus IL-13 KTORML GFCPHKVSAGQFSSL VRDTKIEVAQFVKDLL KTORML GFCPHKVSAGQFSSL VRDTKIEVAOFVKDLL 130 Human IL-13 HLKKLFREGOFN (SEQ 10 NO: 173) Cynomolgus IL-13 HLKKLFREGOPN (SEQ 10 NO; 174) HLKKLFREG FN SEQIONOTAY8

Figure 20

Effect of a single 10mg/kg dose of BAK502C9 (IgG4) on serum IgE levels in allergic but non-challenged cynomolgus monkeys



Time (b)

°p<0.05

23/24





Figure 30

24/24

PCT/GB2004/003059



(SER ID NO: 173)

Figure 32

SLHVRDTKIE VAOFVKOLLE HLKKLFREGR FN